About: Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19)
Creator	Catravas, John Chow, Vincent Berrill, Max Biancatelli, Luciano Colunga Biancatelli, Luciano Manuel, Ruben Marik, Paul
source	Medline; PMC
abstract	Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) represents an emergent global threat which is straining worldwide healthcare capacity. As of May 27th, the disease caused by SARS-CoV-2 (COVID-19) has resulted in more than 340,000 deaths worldwide, with 100,000 deaths in the US alone. It is imperative to study and develop pharmacological treatments suitable for the prevention and treatment of COVID-19. Ascorbic acid is a crucial vitamin necessary for the correct functioning of the immune system. It plays a role in stress response and has shown promising results when administered to the critically ill. Quercetin is a well-known flavonoid whose antiviral properties have been investigated in numerous studies. There is evidence that vitamin C and quercetin co-administration exerts a synergistic antiviral action due to overlapping antiviral and immunomodulatory properties and the capacity of ascorbate to recycle quercetin, increasing its efficacy. Safe, cheap interventions which have a sound biological rationale should be prioritized for experimental use in the current context of a global health pandemic. We present the current evidence for the use of vitamin C and quercetin both for prophylaxis in high-risk populations and for the treatment of COVID-19 patients as an adjunct to promising pharmacological agents such as Remdesivir or convalescent plasma.
has issue date	2020-06-19(xsd:dateTime)
bibo:doi	10.3389/fimmu.2020.01451
bibo:pmid	32636851
has license	cc-by
sha1sum (hex)	67830583a9997c78e707412b3acd7fa9e09d2127
schema:url	https://doi.org/10.3389/fimmu.2020.01451
resource representing a document's title	Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19)
has PubMed Central identifier	PMC7318306
has PubMed identifier	32636851
schema:publication	Front Immunol
resource representing a document's body	covid:67830583a9997c78e707412b3acd7fa9e09d2127#body_text
is schema:about of	named entity 'Severe Acute Respiratory Syndrome Coronavirus' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'sound' named entity 'pandemic' named entity 'Related' named entity 'THREAT' named entity 'VITAMIN C' named entity 'PREVENTION' named entity 'SYNERGISTIC' named entity 'EXERTS' named entity 'PLAYS' named entity 'investigated' named entity 'synergistic' named entity 'Prevention' named entity 'Remdesivir' named entity 'global health' named entity 'synergistic' named entity 'antiviral' named entity 'COVID-19' named entity 'antiviral' named entity 'COVID' named entity 'antiviral' named entity 'quercetin' named entity 'recycle' named entity 'large intestine' named entity 'toxicity' named entity 'murine models' named entity 'integrase' named entity 'inducible nitric oxide synthase' named entity 'influenza infection' named entity 'quercetin' named entity 'quercetin' named entity 'interferon' named entity 'type 1' named entity 'quercetin' named entity 'subcutaneous injection' named entity 'parainfluenza' named entity 'quercetin' named entity 'quercetin' named entity 'herpes simplex keratitis' named entity 'IFN' named entity 'trimethyl' named entity 'vitamins' named entity 'cytomegalovirus' named entity 'ascorbic acid' named entity 'HSP40' named entity 'vitamin' named entity 'phosphorylation' named entity 'minimum inhibitory concentration' named entity 'plaque formation' named entity 'influenza' named entity 'anti-viral' named entity 'ascorbate' named entity 'quercetin' named entity 'ascorbate' named entity 'SARS-Cov' named entity 'antiviral' named entity 'maximum plasma concentration' named entity 'foreskin' named entity 'antibody titer' named entity 'hydroxyl groups' named entity 'FDA' named entity 'SARS-CoV-2' named entity 'Intravenous administration' named entity 'antiviral' named entity 'interferon' named entity 'quercetin' named entity 'ascorbate' named entity 'murine leukemia virus' named entity 'ascorbic acid' named entity 'prophylaxis' named entity 'vitamin' named entity 'life-cycle' named entity 'IL-6'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software